Effects and Costs of Hepatitis C Virus Elimination for the Whole Population in China: A Modelling Study
- 2 September 2024
- journal article
- research article
- Published by Springer Nature in PharmacoEconomics
- Vol. 42 (12) , 1345-1357
Abstract
Background and Objective China has the highest number of hepatitis C virus (HCV) infections in the world. However, it is unclear what levels of screening and treatment are needed to achieve the WHO 2030 hepatitis C elimination targets. We aimed to evaluate the impact of scaling up interventions on the hepatitis C epidemic and determine how and at what cost these elimination targets could be achieved for the whole population in China. Methods We developed a compartmental model incorporating HCV transmission, disease progression, and care cascade for the whole population in China, calibrated with data on demographics, injecting drug use, HCV prevalence, and treatments. Five different scenarios were evaluated for effects and costs for 2022–2030. All costs were converted to 2021 US dollar (USD) and discounted at an annual rate of 5%. One-way sensitivity analyses were conducted to assess the robustness of the model. Results Under the status quo scenario, the incidence of hepatitis C is projected to increase from 60.39 (57.60–63.45) per 100,000 person-years in 2022 to 68.72 (65.3–73.97) per 100,000 person-years in 2030, and 2.52 million (1.94–3.07 million) infected patients are projected to die between 2022 and 2030, of which 0.76 (0.61–1.08) million will die due to hepatitis C. By increasing primary screening to 10%, conducting regular rescreening (annually for PWID and every 5 years for the general population) and treating 90% of patients diagnosed, the incidence would be reduced by 88.15% (86.61–89.45%) and hepatitis C-related mortality by 60.5% (52.62–65.54%) by 2030, compared with 2015 levels. This strategy would cost USD 52.78 (USD 43.93–58.53) billion. Conclusions Without changes in HCV prevention and control policy, the disease burden of HCV in China will increase dramatically. To achieve the hepatitis C elimination targets, China needs to sufficiently scale up screening and treatment.Keywords
Funding Information
- National Natural Science Foundation of China (71874209)
- research project of the Health Commission of Hunan province (202113050283)
- Fundamental Research Funds for Central Universities of the Central South University (2023ZZTS0924)
- Natural Science Foundation of Hunan Province (2023JJ60503)
This publication has 34 references indexed in Scilit:
- Universal screening and treatment towards the elimination of chronic hepatitis C in China: an economic evaluationPublic Health, 2024
- Cost-effectiveness of universal screening for chronic hepatitis B virus infection in China: an economic evaluationThe Lancet Global Health, 2022
- A Tool to Inform Hepatitis C Elimination: A Case for Hepatitis C Elimination in ChinaClinical Liver Disease, 2021
- Effects and cost of different strategies to eliminate hepatitis C virus transmission in Pakistan: a modelling analysisThe Lancet Global Health, 2020
- The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level: a modelling studyThe Lancet Gastroenterology & Hepatology, 2019
- Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic reviewThe Lancet Global Health, 2017
- Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling studyThe Lancet Gastroenterology & Hepatology, 2017
- Estimating the burden of disease attributable to injecting drug use as a risk factor for HIV, hepatitis C, and hepatitis B: findings from the Global Burden of Disease Study 2013The Lancet Infectious Diseases, 2016
- Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviewsThe Lancet, 2011
- Estimation of stage‐specific fibrosis progression rates in chronic hepatitis C virus infectionHepatology, 2008